Efficacy of moxifloxacin (avelox) in prophylaxis of infection in patients with profound neutropenia

Antibiotiki i Khimioterapiya

Volumn 49, Issue 3, 2004, Pages 26-31

  Minenko, S V ^a   Dmitrieva, N V ^a   Sokolova, E N ^a   Zhukov, N V ^a   Ptushkin, V V ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Ciprofloxacin; Infection prevention; Moxifloxacin; Severe neutropenic patients

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; QUINOLINES;

EID: 6344289091     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pizzo P. A. Antibiotic prophylaxis in the immunosupressed patient with cancer. Curr Clin Top Infect Dis 1983; 4:153
2. Hughes W. T, Armstrong D., Bodey G. P et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. New York; 2002.
3. Tunkel A. R., Sepkowitz K. A. Clin Infect Dis 2002; 1: 34: 11: 1524-1529.
4. Cuiot B., Van Furth R. Selective decontamination in bone marrow transplant recipients. Epid Infect 1992; 109: 349-360.
5. Mouin F., Chandrasehar B. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 323: 205-215.
6. Donowitz G. R, Rolston V. I. et al. Infections in the Neutropenic Patient-New Views of an Old Problem Hematology. The American Society of Hematology. 2001.
7. Humpreus H. Medical Microbiology. A Guide to Microbial Infections, Immunity Laboratory Diagnosis and Control. Edited by Greenwood. London, 1997; 170-183.
8. Rolstov V. K, Road I, Bodey G. P. The changing spectrum bacterial infections in febrile neutropenic patients. Febr Neutrop 1999; 53-56.
9. Marcetti O., Cometta A., Calandra A. Fluoroquinolone prophylaxis in granulocytopenic cancer patients: pro and con's. 5th Inthern Symp Febrile Neutropenia, Brussels, 2001.
10. Cruciani M., Malena M., Nardi S. et al. A reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolones in neutropenic cancer patients. 42nd ICAAC Abstr, San Diego; 2002; 367.
11. Jones R. N. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495-502.
12. Doern G. V., Ferraro M. J., Brueggemann A., Ruoff K. L. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996; 40: 891-894.
13. Pfaller M. A., Marshall S. A., Jones R. N. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample. Diagn Microbial Infect Dis 1997; 29: 273-276.
14. Rodriguez-Avial I., Rodriguez-Avial C., Picazo J. J. In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin, Rev Esp Quimioter 2001; 14: 364-368.
15. Karp Y. E, Merz W. G et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med. 1987; 106: 1-7.
16. Talbot G. H, Cassilet P. A, Paradiso L. et al. Infection prophylaxis Study Group/ Oral enoxacin for infection prevention in adults with acute non-lymphocytic leukemia. Antimicrob Agents Chemother 1993; 37: 474-482.
17. Vinston D. Y, Vinston G. H et al. Ofloxacin versus vancomycin/polymyxin for prevention of infection in granulocytopenic patients. Am J Med 1990; 88: 36-42.
18. Cruciani M., Rampazzo R., Malena M. et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect dis. 1996; 23: 795-805.
19. Engels E. A, Lau J., Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a metaanalysis. J Clin Oncol 1998; 16: 1179-1187.
20. Delarive P., Baumgartner J. D. et al. Evaluation de la prophylaxi antibiotique chez les patients neutropeuniques avec hemopathie maligne. Schweiz Med Wochens 2000; 130: 1837-1844.
21. Russian source